Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study

Vaccine

Volumn 33, Issue 36, 2015, Pages 4594-4601

  Hatz, Christoph F R ^a,d   Bally, Bettina ^a   Rohrer, Susanne ^c   Steffen, Robert ^a   Kramme, Stefanie ^d   Siegrist, Claire Anne ^b   Wacker, Michael ^c   Alaimo, Cristina ^c   Fonck, Veronica Gambillara ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c GlycoVaxyn AG   (Switzerland)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Bioconjugate; Immunogenicity; Reactogenicity; Safety; Shigella; Vaccine

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CONTRACEPTIVE AGENT; EXOTOXIN; EXOTOXIN PROTEIN A; GVXN SD 133; HEPATITIS A VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VACCINE; LIPOPOLYSACCHARIDE; POLYSACCHARIDE; TICK BORNE ENCEPHALITIS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE; BACTERIAL TOXIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; DRUG CARRIER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; O ANTIGEN; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VIRULENCE FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; MALE; MORTALITY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SHIGELLA DYSENTERIAE; SHIGELLOSIS; SINGLE BLIND PROCEDURE; ADOLESCENT; BLOOD; CLINICAL TRIAL; DYSENTERY, BACILLARY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADP RIBOSE TRANSFERASES; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; BACTERIAL VACCINES; DRUG CARRIERS; DYSENTERY, BACILLARY; EXOTOXINS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; O ANTIGENS; SHIGELLA DYSENTERIAE; SINGLE-BLIND METHOD; VACCINES, CONJUGATE; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84939566263     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.102     Document Type: Article

References (40)

1. WHO Guidelines for the control of shigellosis, including epidemics due to Shigella dysentaeriae type 1 2005, WHO, Geneva, Switzerland.
2. Niyogi S.K., Mitra U., Dutta P. Changing patterns of serotypes and antimicrobial susceptibilities of Shigella species isolated from children in Calcutta, India. Jpn J Infect Dis 2001, 54:121-122.
3. Livio S., et al. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin Infect Dis 2014, 59:933-941. (An Official Publication of the Infectious Diseases Society of America).
4. Jones F.R., et al. Short report. High incidence of shigellosis among Peruvian soldiers deployed in the Amazon River basin. Am J Trop Med Hyg 2004, 70:663-665.
5. Ahmed S.F., et al. Epidemiology and genetic characterization of Shigella flexneri strains isolated from three paediatric populations in Egypt (2000-2004). Epidemiol Infect 2006, 134:1237-1248.
6. Abu-Elyazeed R.R., et al. Epidemiology of Shigella-associated diarrhea in rural Egyptian children. Am J Trop Med Hyg 2004, 71:367-372.
7. Orr N., et al. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 2005, 73:8027-8032.
8. Bercion R., et al. Molecular epidemiology of multidrug-resistant Shigella dysenteriae type 1 causing dysentery outbreaks in Central African Republic, 2003-2004. Trans R Soc Trop Med Hyg 2006, 100:1151-1158.
9. Pazhani G.P., et al. Clonal multidrug-resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern India. Antimicrob Agents Chemother 2004, 48:681-684.
10. Shears P. Shigella infections. Ann Trop Med Parasitol 1996, 90(Apr. (2)):105-114.
11. Kotloff K.L., et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS). A prospective, case-control study. Lancet 2013, 382:209-222.
12. Bennish M.L., Salam M.A., Haider R., Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. Braz J Infect Dis 1990, 162:711-716.
13. Agtini M.D., et al. The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance. BMC Infect Dis 2005, 5:89.
14. Seidlein L., von, et al. A multicentre study of Shigella diarrhoea in six Asian countries. Disease burden, clinical manifestations, and microbiology. PLoS Med 2006, 3:e353.
15. Barry E.M., et al. Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol 2013, 10:245-255.
16. Comerci D.J., Pollevick G.D., Vigliocco A.M., Frasch A.C., Ugalde R.A. Vector development for the expression of foreign proteins in the vaccine strain Brucella abortus S19. Infect Immun 1998, 66:3862-3866.
17. Rahman K.M., et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in MatLab, Bangladesh. Vaccine 2011, 29:1347-1354.
18. McKenzie R., et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei. Preclinical studies and a Phase I trial. Vaccine 2006, 24:3735-3745.
19. Venkatesan M., Ranallo R.T. Live-attenuated Shigella vaccines. Expert Rev Vaccines 2006, 5:669-686.
20. Holmgren J., Svennerholm A.-M. Vaccines against mucosal infections. Curr Opin Immunol 2012, 24:343-353.
21. Robbins J.B., Chu C., Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis 1992, 15:346-361.
22. Cohen D., et al. Safety and immunogenicity of the oral E. coli K12-S. Flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers. Vaccine 1994, 12:1436-1442.
23. Cohen D., et al. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun 1996, 64:4074-4077.
24. Ashkenazi S., et al. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis 1999, 179:1565-1568.
25. Passwell J.H., et al. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr Infect Dis J 2003, 22:701-706.
26. Passwell J.H., et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 2009, 28:2231-2235.
27. Passwell J.H., et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001, 69:1351-1357.
28. Fernandez F., Wacker M. Synthesis of glycoconjugate vaccines in genetically engineered bacterial cells. COC 2014, 18:960-963.
29. Feldman M.F., et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA 2005, 102:3016-3021.
30. Wacker M., et al. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis 2014, 209:1551-1561.
31. Kowarik M., et al. Definition of the bacterial N-glycosylation site consensus sequence. EMBO J 2006, 25:1957-1966.
32. Fattom A., et al. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 1990, 58:2367-2374.
33. Fattom A., et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993, 61:1023-1032.
34. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines. Two steps forward and one step back on a long, hard road. Nat Rev 2007, 5:540-553.
35. Wuorimaa T., Kayhty H. Current state of pneumococcal vaccines. Scand J Immunol 2002, 56:111-129.
36. Hedari C.P., Khinkarly R.W., Dbaibo G.S. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist 2014, 7:85-99.
37. 197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS ONE 2011, 6:e25398.
38. Robbins J.B., Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis 1990, 161:821-832.
39. Taylor D.N., et al. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun 1993, 61:3678-3687.
40. Huebner R.E., et al. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine 2004, 23:802-806.